Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BEAM Beam Therapeutics	$19.93 +1.1%	$21.62	$13.53 ▼ $35.25	$2.00B	2.02	1.39 million shs	2.08 million shs
BHC Bausch Health Companies	$5.28 -4.2%	$6.14	$3.96 ▼ $9.85	$1.95B	0.43	2.70 million shs	2.31 million shs
MIRM Mirum Pharmaceuticals	$43.45 +2.1%	$43.51	$23.83 ▼ $54.23	$2.15B	1	521,198 shs	351,176 shs
PRTA Prothena	$9.20 -5.1%	$12.10	$9.00 ▼ $25.42	$495.21M	0.07	502,124 shs	989,315 shs

2025 Gold Forecast: A Perfect Storm for Demand

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BEAM Beam Therapeutics	-0.45%	+3.03%	-11.26%	-23.93%	-10.61%
BHC Bausch Health Companies	+1.66%	+5.87%	-15.19%	-26.32%	-38.13%
MIRM Mirum Pharmaceuticals	+2.98%	+7.89%	-7.50%	-12.47%	+69.68%
PRTA Prothena	+0.41%	+1.57%	-26.26%	-38.71%	-54.27%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
BEAM Beam Therapeutics	3.0229 of 5 stars	4.5	1.0	0.0	2.4	2.5	0.6
BHC Bausch Health Companies	4.1992 of 5 stars	2.9	3.0	4.0	2.6	1.7	1.9
MIRM Mirum Pharmaceuticals	4.2328 of 5 stars	3.5	1.0	4.2	3.6	3.3	0.6
PRTA Prothena	3.4126 of 5 stars	4.4	2.0	0.0	3.0	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BEAM Beam Therapeutics	3.00	Buy	$49.45	148.14% Upside
BHC Bausch Health Companies	1.86	Reduce	$7.17	35.73% Upside
MIRM Mirum Pharmaceuticals	3.09	Buy	$58.20	33.95% Upside
PRTA Prothena	2.75	Moderate Buy	$55.00	497.83% Upside

Current Analyst Ratings Breakdown

Latest PRTA, MIRM, BHC, and BEAM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
4/7/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
4/7/2025	BHC Bausch Health Companies	Royal Bank of Canada Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Sector Perform	$9.00 ➝ $8.50
3/28/2025	BEAM Beam Therapeutics	Bank of America Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Neutral ➝ Buy	$42.00 ➝ $42.00
3/12/2025	BEAM Beam Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Overweight
3/10/2025	BEAM Beam Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Hold ➝ Buy	$34.00
3/10/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
3/10/2025	BEAM Beam Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$57.00
3/10/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$40.00
3/3/2025	BEAM Beam Therapeutics	Scotiabank Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Sector Perform ➝ Sector Perform	$24.00 ➝ $25.00
2/28/2025	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
2/28/2025	MIRM Mirum Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$66.00 ➝ $72.00

(Data available from 4/30/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BEAM Beam Therapeutics	$63.52M	31.55	N/A	N/A	$12.04 per share	1.66
BHC Bausch Health Companies	$9.63B	0.20	$5.62 per share	0.94	($0.89) per share	-5.93
MIRM Mirum Pharmaceuticals	$336.89M	6.38	N/A	N/A	$5.33 per share	8.15
PRTA Prothena	$135.16M	3.66	N/A	N/A	$10.46 per share	0.88

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BEAM Beam Therapeutics	-$132.53M	-$4.58	N/A	N/A	N/A	-41.07%	-16.22%	-10.94%	5/6/2025 (Estimated)
BHC Bausch Health Companies	-$46M	-$0.12	N/A	1.13	0.37	-0.48%	-577.82%	5.24%	4/30/2025 (Estimated)
MIRM Mirum Pharmaceuticals	-$163.41M	-$1.85	N/A	N/A	N/A	-31.69%	-41.22%	-14.81%	5/6/2025 (Estimated)
PRTA Prothena	-$147.03M	-$2.30	N/A	N/A	N/A	-90.50%	-22.67%	-19.68%	5/6/2025 (Estimated)

Latest PRTA, MIRM, BHC, and BEAM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MIRM Mirum Pharmaceuticals	-$0.35	N/A	N/A	N/A	N/A	N/A
5/14/2025	Q1 2025	PRTA Prothena	-$0.92	N/A	N/A	N/A	$8.18 million	N/A
5/6/2025	Q1 2025	BEAM Beam Therapeutics	-$1.11	N/A	N/A	N/A	$14.69 million	N/A
4/30/2025	Q1 2025	BHC Bausch Health Companies	$1.46	$0.59	-$0.87	-$0.16	$2.29 billion	N/A
2/26/2025	Q4 2024	MIRM Mirum Pharmaceuticals	-$0.27	-$0.49	-$0.22	-$0.49	$96.64 million	$99.41 million
2/25/2025	Q4 2024	BEAM Beam Therapeutics	-$1.25	-$1.09	+$0.16	-$1.09	$16.47 million	$30.00 million
2/20/2025	Q4 2024	PRTA Prothena	-$1.02	-$1.08	-$0.06	-$1.08	$7.53 million	$2.12 million
2/19/2025	Q4 2024	BHC Bausch Health Companies	$1.65	$1.21	-$0.44	$0.25	$2.51 billion	$2.56 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
BEAM Beam Therapeutics	$0.90	4.52%	N/A	N/A	N/A
BHC Bausch Health Companies	N/A	N/A	N/A	N/A	N/A
MIRM Mirum Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
PRTA Prothena	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BEAM Beam Therapeutics	N/A	5.69	5.69
BHC Bausch Health Companies	N/A	0.86	0.62
MIRM Mirum Pharmaceuticals	1.33	3.34	3.15
PRTA Prothena	N/A	11.52	11.52

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BEAM Beam Therapeutics	99.68%
BHC Bausch Health Companies	78.65%
MIRM Mirum Pharmaceuticals	N/A
PRTA Prothena	97.08%

Insider Ownership

Company	Insider Ownership
BEAM Beam Therapeutics	4.20%
BHC Bausch Health Companies	8.12%
MIRM Mirum Pharmaceuticals	22.87%
PRTA Prothena	9.20%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BEAM Beam Therapeutics	510	100.56 million	79.33 million	Optionable
BHC Bausch Health Companies	19,900	369.51 million	338.06 million	Optionable
MIRM Mirum Pharmaceuticals	140	49.45 million	37.03 million	Optionable
PRTA Prothena	130	53.83 million	38.64 million	Optionable

PRTA, MIRM, BHC, and BEAM Headlines

Recent News About These Companies

Prothena (NASDAQ:PRTA) Trading Down 2.4% - What's Next?

April 30 at 1:35 PM | marketbeat.com

Birchview Capital LP Buys 95,000 Shares of Prothena Co. plc (NASDAQ:PRTA)

April 28 at 6:53 AM | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Price Up 7.7% - Still a Buy?

April 23, 2025 | marketbeat.com

JPMorgan Chase & Co. Purchases 187,364 Shares of Prothena Co. plc (NASDAQ:PRTA)

April 20, 2025 | marketbeat.com

Vanguard Group Inc. Boosts Stake in Prothena Co. plc (NASDAQ:PRTA)

April 19, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Hits New 12-Month Low - What's Next?

April 18, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Price Down 5.4% - What's Next?

April 17, 2025 | marketbeat.com

Norges Bank Invests $796,000 in Prothena Co. plc (NASDAQ:PRTA)

April 14, 2025 | marketbeat.com

Federated Hermes Inc. Increases Stock Holdings in Prothena Co. plc (NASDAQ:PRTA)

April 13, 2025 | marketbeat.com

Prothena Co. plc (NASDAQ:PRTA) Given Average Rating of "Moderate Buy" by Brokerages

April 13, 2025 | marketbeat.com

Massachusetts Financial Services Co. MA Invests $621,000 in Prothena Co. plc (NASDAQ:PRTA)

April 12, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Price Down 9.6% - What's Next?

April 11, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Reaches New 1-Year Low - Here's What Happened

April 9, 2025 | marketbeat.com

Finepoint Capital LP Grows Position in Prothena Co. plc (NASDAQ:PRTA)

April 8, 2025 | marketbeat.com

Prothena Co. plc (NASDAQ:PRTA) Shares Acquired by Wellington Management Group LLP

April 7, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Reaches New 12-Month Low - Here's What Happened

April 2, 2025 | marketbeat.com

Prothena (NASDAQ:PRTA) Stock Price Down 7.2% - Time to Sell?

April 1, 2025 | marketbeat.com

Prothena Corporation: Multiple Failures Make It Risky

March 3, 2025 | seekingalpha.com

Prothena price target raised to $110 from $94 at Piper Sandler

February 26, 2025 | markets.businessinsider.com

Prothena Reports 2024 Financial Results and 2025 Outlook

February 22, 2025 | tipranks.com

Prothena’s Balanced Earnings Call Highlights Growth and Challenges

February 22, 2025 | tipranks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRTA, MIRM, BHC, and BEAM Company Descriptions

Beam Therapeutics NASDAQ:BEAM

$19.93 +0.22 (+1.12%)

As of 04:00 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

Bausch Health Companies NYSE:BHC

$5.28 -0.23 (-4.17%)

As of 03:59 PM Eastern

Bausch Health Companies Inc. operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health. The company operates through five segments: Salix, International, Solta Medical, Diversified, and Bausch + Lomb. The Salix segment provides gastroenterology products in the United States. The International segment sells aesthetic medical devices, branded pharmaceuticals, generic pharmaceuticals, and OTC products internationally. The Solta Medical segment engages in the sale of aesthetic medical devices. The Diversified segment offers pharmaceutical products in the areas of neurology and certain other therapeutic classes; generic products; ortho dermatologic; and dentistry products in the United States. The Bausch + Lomb segment offers products in the areas of vision care, surgical, and ophthalmic pharmaceuticals products. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Mirum Pharmaceuticals NASDAQ:MIRM

$43.45 +0.91 (+2.14%)

As of 04:00 PM Eastern

Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is approved as treatment for pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects and for adjunctive treatment of patients with peroxisomal disorders, including peroxisome biogenesis disorder-Zellweger spectrum disorder and Smith-Lemli-Opitz syndrome; and Chenodal, a tablet, which is approved for the treatment of radiolucent stones in the gallbladder, and under Phase 3 development for the treatment cerebrotendinous xanthomatosis. In addition, it develops Volixibat, an oral and minimally absorbed agent designed to inhibit IBAT, currently under Phase 2b clinical trial for the treatment of adult patients with cholestatic liver diseases. The company was incorporated in 2018 and is headquartered in Foster City, California.

Prothena NASDAQ:PRTA

$9.20 -0.49 (-5.06%)

As of 04:00 PM Eastern

Prothena Corporation plc, a late-stage clinical biotechnology company, focuses on discovery and development of novel therapies to treat diseases caused by protein dysregulation in the United States. The company is involved in developing birtamimab, an investigational humanized antibody that is in Phase III clinical trial for the treatment of AL amyloidosis; Prasinezumab, a humanized monoclonal antibody, for the treatment of Parkinson's disease and other related synucleinopathies which is in Phase IIb clinical trial; NNC6019 that is in Phase lI clinical trial for the treatment of ATTR amyloidosis; and BMS-986446 and PRX012, which is in Phase I clinical trial for the treatment of Alzheimer's disease. Its discovery and preclinical programs include PRX123, a dual Aß-Tau vaccine for the treatment and prevention of Alzheimer's disease; and PRX019 for the treatment of neurogenerative diseases, as well as TDP-43 for the treatment of amyotrophic lateral sclerosis. Prothena Corporation plc has a license, development, and commercialization agreement with F. Hoffmann-La Roche Ltd. and Hoffmann-La Roche Inc. to develop and commercialize antibodies that target a-synuclein, including prasinezumab; and a collaboration agreement with Bristol-Myers Squibb to develop and commercialize antibodies targeting tau, TDP-43. The company was incorporated in 2012 and is based in Dublin, Ireland.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time